Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M, Berry W (1996) J Clin Oncol 14: 1913-21 Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J (2000) J Clin Oncol 18: 609-22 Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI (1994) J Clin Oncol 12: 1553-60 Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M (1993) J Clin Oncol 11: 22-8 Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW, Fletcher WS, Weiss GR, Unger JM, Sondak VK (1998) J Clin Oncol 16: 664-9 High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Hainsworth JD, Burnett LS, Jones HW, Grosh WW, Johnson DH, Greco FA (1990) J Clin Oncol 8: 502-8 Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W (2001) J Clin Oncol 19: 3194-202 A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M (1994) J Natl Cancer Inst 86: 673-80 Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL (1997) J Natl Cancer Inst 89: 365-73 Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA (1988) Ann Intern Med 108: 165-70 Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Strnad CM, Grosh WW, Baxter J, Burnett LS, Jones HW, Greco FA, Hainsworth JD (1989) Ann Intern Med 111: 213-7 KIM-1-mediated phagocytosis reduces acute injury to the kidney. Yang L, Brooks CR, Xiao S, Sabbisetti V, Yeung MY, Hsiao LL, Ichimura T, Kuchroo V, Bonventre JV (2015) J Clin Invest 125: 1620-36 Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. Brooks C, Wei Q, Cho SG, Dong Z (2009) J Clin Invest 119: 1275-85 Copy number polymorphisms and anticancer pharmacogenomics. Gamazon ER, Huang RS, Dolan ME, Cox NJ (2011) Genome Biol 12: R46 Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH (1997) Blood 90: 935-43 Cytoprotective effects of hypoxia against cisplatin-induced tubular cell apoptosis: involvement of mitochondrial inhibition and p53 suppression. Wang J, Biju MP, Wang MH, Haase VH, Dong Z (2006) J Am Soc Nephrol 17: 1875-85 Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M, Noiri E (2013) J Am Soc Nephrol 24: 2034-43 Failure of chronic glutathione elevation to reduce cytotoxicity produced by exposure to cis-diamminedichloroplatinum(II), ionizing radiation, or hyperthermia. Freeman ML, Meredith MJ, Eisert DR (1990) Cancer Res 50: 5296-300 p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ (1994) Cancer Res 54: 3758-65 Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Dias CS, Liu Y, Yau A, Westrick L, Evans SC (2006) Cancer Res 66: 9467-73 Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Katagiri D, Hamasaki Y, Doi K, Negishi K, Sugaya T, Nangaku M, Noiri E (2016) Kidney Int 89: 374-85 Mild elevation of urinary biomarkers in prerenal acute kidney injury. Doi K, Katagiri D, Negishi K, Hasegawa S, Hamasaki Y, Fujita T, Matsubara T, Ishii T, Yahagi N, Sugaya T, Noiri E (2012) Kidney Int 82: 1114-20 Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Clin Cancer Res 5: 1007-14 Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Brader KR, Wolf JK, Hung MC, Yu D, Crispens MA, van Golen KL, Price JE (1997) Clin Cancer Res 3: 2017-24 A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M (2012) Clin Cancer Res 18: 1735-42 Variants in and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB (2017) Clin Cancer Res 23: 3325-3333 A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA (2017) Clin Cancer Res 23: 4035-4045 Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW (2006) Clin Cancer Res 12: 1897-905 Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW (2010) Clin Cancer Res 16: 1834-44 A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A (2015) Clin Cancer Res 21: 1566-73 A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW (2002) Clin Cancer Res 8: 3075-81 Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF (2001) Clin Cancer Res 7: 68-73 Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML (2008) Clin Cancer Res 14: 7947-55 Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB, Platinum Study Group (2017) Clin Cancer Res 23: 5757-5768 Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassivi SD, Montero AJ, Schefter TE, American College of Surgeons Oncology Group (2014) Ann Oncol 25: 1039-44 Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L (2017) Ann Oncol 28: 777-783 Challenges in interpreting the evidence for genetic predictors of ototoxicity. Ratain MJ, Cox NJ, Henderson TO (2013) Clin Pharmacol Ther 94: 631-5 Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014) Oncotarget 5: 5637-50 Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A, Shinohara M, Ando Y (2015) Oncotarget 6: 1008-19 The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A, El-Rifai W (2012) Mol Cancer Ther 11: 763-74
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.